|Common names||Allylescaline, AL|
|Routes of Administration|
|Summary sheet: Allylescaline|
Allylescaline, AL or 4-allyloxy-3,5-dimethoxyphenethylamine is a psychedelic drug and entheogen of the phenethylamine class of compounds. It is relatively uncommon and has little to no history of human usage. Very little data exists about the pharmacological properties, metabolism, and toxicity of allylescaline.
The effects of this compound were first described by Alexander Shulgin in his book PiHKAL: A Chemical Love Story. He lists the dosage range as 20 – 35 mg orally and describes the duration of action to be 8 - 12 hours.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal issues
- 6 See also
- 7 External links
- 8 References
Allylescaline, or 4-allyloxy-3,5-dimethoxyphenethylamine, is a substituted phenethylamine featuring a phenyl ring bound to an amino -NH2 group through an ethyl chain. Escaline contains two methoxy functional groups CH3O- which are attached to carbons R3, and R5 and an additional allyloxy group at carbon R4 of the phenyl ring. Allylescaline is the 4-allyloxy analog of mescaline.
Allylescaline acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from allylescaline's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
Disclaimer: The effects listed below are cited from the subjective effect index, which is based on anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be treated with a healthy degree of skepticism. It is worth noting that these effects will rarely (if ever) occur all at once, although higher doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- After images
- Brightness alteration
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational allylescaline use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because allylescaline is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried allylescaline suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
Allylescaline is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of allylescaline are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). Allylescaline presents cross-tolerance with all psychedelics, meaning that after the consumption of allylescaline all psychedelics will have a reduced effect.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- Germany: Allylescaline is controlled under BtMG Anlage I, making it illegal to manufacture, import, possess, sell, or transfer it without a license.
- United Kingdom - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
- https://www.erowid.org/library/books_online/pihkal/pihkal002.shtml | Allylescaline (TiHKAL)
- Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted